全血细胞减少症的病因不同,临床变化及骨髓象亦不一致,故预后难以估计。半数患者被认为属原发性,部分病例可能与免疫有关。除与感染或药物等有关外,有些病例为白血病前期的变化。通常应用对症治疗,如肾上腺皮质激素,免疫抑制剂及脾切除术。但对脾切除术的效果目前还有不同的看法。 1967～1971年间作者曾对19个病人进行脾切除,9例获得完全缓解,骨髓中三个系统的细胞转为正常,继续门诊观察甚为满意,4例血象改善。6例手术后数周死于出血并发症,但与手术本身无关,尸检发现其中2例系继发于“恶网”病的全血细胞减少。作者认为该病以往仅限于消除可能中毒因素、反复输血、以及激素等一般治疗。本组先用激素治疗6个 The cause of pancytopenia is different, clinical changes and bone marrow are not the same, so the prognosis is difficult to estimate. Half of the patients are considered as primary and some cases may be related to immunity. In addition to infection or drug-related, some cases of pre-leukemia changes. Symptomatic treatment is usually used, such as adrenal hormones, immunosuppressive agents and splenectomy. But the effect of splenectomy there are different views. Between 1967 and 1971, the authors performed splenectomy on 19 patients, complete remission in 9 patients, normalization of the three systems in the bone marrow, continued satisfaction with outpatient visits, and improvement of the blood picture in 4 patients. Six patients died of bleeding complications several weeks after surgery, but nothing to do with the surgery itself. Two of the autopsy findings were pancytopenia secondary to “nets”. The authors believe that the disease in the past only to eliminate possible poisoning factors, repeated blood transfusions, and hormones and other general treatment. This group first with hormone treatment of six